{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:07:05Z","timestamp":1793326025039,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11030-024-10964-z","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T03:24:19Z","timestamp":1723865059000},"page":"2691-2716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advancements in targeting tumor suppressor genes (p53 and BRCA 1\/2) in breast cancer therapy"],"prefix":"10.1007","volume":"29","author":[{"family":"Chahat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Nainwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Murti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"10964_CR1","doi-asserted-by":"publisher","first-page":"1053035","DOI":"10.3389\/fonc.2022.1053035","volume":"12","author":"E De Paolis","year":"2023","unstructured":"De Paolis E, Paris I, Tilocca B, Roncada P, Foca L, Tiberi G, D\u2019Angelo T, Pavese F, Muratore M, Carbognin L (2023) Assessing the pathogenicity of BRCA1\/2 variants of unknown significance: relevance and challenges for breast cancer precision medicine. Front Oncol 12:1053035","journal-title":"Front Oncol"},{"key":"10964_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram I, Bray F (2021) Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070. Nat Rev Clin Oncol 18:663\u2013672","journal-title":"Nat Rev Clin Oncol"},{"key":"10964_CR3","doi-asserted-by":"publisher","DOI":"10.14218\/JERP.2023.00054","author":"S Kaur","year":"2023","unstructured":"Kaur S, Singh D (2023) Genetic contribution to breast cancer: a critical analysis of penetrance alleles as susceptible genes. J Exploratory Res Pharmacol. https:\/\/doi.org\/10.14218\/JERP.2023.00054","journal-title":"J Exploratory Res Pharmacol"},{"key":"10964_CR4","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1002\/mgg3.879","volume":"7","author":"YM Hawsawi","year":"2019","unstructured":"Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM (2019) The role of BRCA1\/2 in hereditary and familial breast and ovarian cancers. Mol Genet Genomic Med 7:e879","journal-title":"Mol Genet Genomic Med"},{"key":"10964_CR5","first-page":"265","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Link Consort, Am j human genet 56:265","journal-title":"Breast Cancer Link Consort, Am j human genet"},{"key":"10964_CR6","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","volume":"77","author":"EB Claus","year":"1996","unstructured":"Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer: Interdiscip Int J Am Cancer Soc 77:2318\u20132324","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"10964_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2022.12.001","volume":"67","author":"Q Ain","year":"2023","unstructured":"Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE (2023) Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients? The Breast 67:30\u201335","journal-title":"The Breast"},{"key":"10964_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","volume":"295","author":"T Walsh","year":"2006","unstructured":"Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379\u20131388","journal-title":"JAMA"},{"key":"10964_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171\u2013182","journal-title":"Cell"},{"key":"10964_CR10","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.1252230","volume":"343","author":"AR Venkitaraman","year":"2014","unstructured":"Venkitaraman AR (2014) Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343:1470\u20131475","journal-title":"Science"},{"key":"10964_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188907","author":"A Wan","year":"2023","unstructured":"Wan A, Zhang G, Ma D, Zhang Y, Qi X (2023) An overview of the research progress of BRCA gene mutations in breast cancer. Biochim et Biophys Acta BBA-Rev Cancer. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188907","journal-title":"Biochim et Biophys Acta BBA-Rev Cancer"},{"key":"10964_CR12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","volume":"32","author":"D Hodgson","year":"2021","unstructured":"Hodgson D, Lai Z, Dearden S, Barrett J, Harrington E, Timms K, Lanchbury J, Wu W, Allen A, Senkus E (2021) Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol 32:1582\u20131589","journal-title":"Ann Oncol"},{"key":"10964_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00240-9","author":"HA Azim","year":"2023","unstructured":"Azim HA, Loutfy SA, Azim HA Jr, Kamal NS, Abdel Fattah NF, Elberry MH, Abdelaziz MR, Abdelsalam M, Aziz M, Shohdy KS (2023) The landscape of BRCA mutations among Egyptian women with breast cancer. Oncol Ther. https:\/\/doi.org\/10.1007\/s40487-023-00240-9","journal-title":"Oncol Ther"},{"key":"10964_CR14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"JM Hall","year":"1990","unstructured":"Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King M-C (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684\u20131689","journal-title":"Science"},{"key":"10964_CR15","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"R Wooster","year":"1994","unstructured":"Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088\u20132090","journal-title":"Science"},{"key":"10964_CR16","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1038\/sj.onc.1203283","volume":"18","author":"GK Dasika","year":"1999","unstructured":"Dasika GK, Lin S-CJ, Zhao S, Sung P, Tomkinson A, Lee EY (1999) DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18:7883\u20137899","journal-title":"Oncogene"},{"key":"10964_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1139\/bcb-2016-0068","volume":"94","author":"DD Scott","year":"2016","unstructured":"Scott DD, Oeffinger M (2016) Nucleolin and nucleophosmin: nucleolar proteins with multiple functions in DNA repair. Biochem Cell Biol 94:419\u2013432","journal-title":"Biochem Cell Biol"},{"key":"10964_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. JNCI: J Nat Cancer Inst 105:812\u2013822","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"10964_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jmg.2006.048173","volume":"44","author":"L Kadouri","year":"2007","unstructured":"Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T (2007) Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations. J Med Genet 44:467\u2013471","journal-title":"J Med Genet"},{"key":"10964_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365\u20131372","journal-title":"J Natl Cancer Inst"},{"key":"10964_CR21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"B.C.L. Consortium","year":"1999","unstructured":"B.C.L. Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310\u20131316","journal-title":"J Natl Cancer Inst"},{"key":"10964_CR22","first-page":"4729","volume":"24","author":"B Kumar","year":"2017","unstructured":"Kumar B, Singh S, Skvortsova I, Kumar V (2017) Promising targets in anti-cancer drug development: recent updates. Curr Med Chem 24:4729\u20134752","journal-title":"Curr Med Chem"},{"key":"10964_CR23","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.esmoop.2022.100459","volume":"7","author":"A Russo","year":"2022","unstructured":"Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M (2022) Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO open 7:100459","journal-title":"ESMO open"},{"key":"10964_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701\u2013713","journal-title":"Nat Rev Cancer"},{"key":"10964_CR25","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.12659\/MSM.890804","volume":"20","author":"A Isik","year":"2014","unstructured":"Isik A, Peker K, Firat D, Yilmaz B, Sayar I, Idiz O, Cakir C, Demiryilmaz I, Yilmaz I (2014) Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: a clinical trial. Med Sci Monit: Int Med J Exp Clin Res 20:1369","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"key":"10964_CR26","doi-asserted-by":"publisher","first-page":"115020","DOI":"10.1016\/j.ejmech.2022.115020","volume":"247","author":"R Bhatia","year":"2023","unstructured":"Bhatia R, Kumar B (2023) p53 as a potential target for treatment of cancer: a perspective on recent advancements in small molecules with structural insights and SAR studies. Eur J Med Chem 247:115020","journal-title":"Eur J Med Chem"},{"key":"10964_CR27","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.12659\/MSM.896260","volume":"22","author":"L Peng","year":"2016","unstructured":"Peng L, Xu T, Long T, Zuo H (2016) Association between BRCA status and P53 status in breast cancer: a meta-analysis. Med Sci Monit: Int Med J Exp Clin Res 22:1939","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"key":"10964_CR28","doi-asserted-by":"publisher","first-page":"a008789","DOI":"10.1101\/cshperspect.a008789","volume":"4","author":"AR Delbridge","year":"2012","unstructured":"Delbridge AR, Valente LJ, Strasser A (2012) The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol 4:a008789","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10964_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature12981","volume":"505","author":"N Rahman","year":"2014","unstructured":"Rahman N (2014) Realizing the promise of cancer predisposition genes. Nature 505:302\u2013308","journal-title":"Nature"},{"key":"10964_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-pathol-042320-025840","volume":"17","author":"M Wang","year":"2022","unstructured":"Wang M, Attardi LD (2022) A balancing act: p53 activity from tumor suppression to pathology and therapeutic implications. Annu Rev Pathol 17:205\u2013226","journal-title":"Annu Rev Pathol"},{"key":"10964_CR31","first-page":"2979","volume":"51","author":"JR Marks","year":"1991","unstructured":"Marks JR, Davidoff AM, Kerns B, Humphrey P, Pence JC, Dodge R, Clarke-Pearson D, Iglehart JD, Bast RC Jr, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Can Res 51:2979\u20132984","journal-title":"Can Res"},{"key":"10964_CR32","doi-asserted-by":"publisher","first-page":"a001883","DOI":"10.1101\/cshperspect.a001883","volume":"1","author":"JT Zilfou","year":"2009","unstructured":"Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1:a001883","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10964_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/0092-8674(92)90562-Q","volume":"71","author":"T Hupp","year":"1992","unstructured":"Hupp T, Meek D, Midgley C, Lane D (1992) Regulation of the specific DNA binding function of p53. Cell 71:875\u2013886","journal-title":"Cell"},{"key":"10964_CR34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1134\/S0006297907130019","volume":"72","author":"P Chumakov","year":"2007","unstructured":"Chumakov P (2007) Versatile functions of p53 protein in multicellular organisms. Biochem Mosc 72:1399\u20131421","journal-title":"Biochem Mosc"},{"key":"10964_CR35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866\u2013871","journal-title":"Cancer Sci"},{"key":"10964_CR36","first-page":"5291","volume":"52","author":"C Coles","year":"1992","unstructured":"Coles C, Condie A, Chetty U, Michael Steel C, John Evans H, Prosser J (1992) p53 mutations in breast cancer. Cancer Res 52:5291\u20135298","journal-title":"Cancer Res"},{"key":"10964_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-019-02055-3","volume":"139","author":"BA Orr","year":"2020","unstructured":"Orr BA, Clay MR, Pinto EM, Kesserwan C (2020) An update on the central nervous system manifestations of Li\u2013Fraumeni syndrome. Acta Neuropathol 139:669\u2013687","journal-title":"Acta Neuropathol"},{"key":"10964_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jcp.10257","volume":"196","author":"EM Rosen","year":"2003","unstructured":"Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Physiol 196:19\u201341","journal-title":"J Cell Physiol"},{"key":"10964_CR39","volume-title":"Mechanism of BRCA1 function","author":"H Zhang","year":"1998","unstructured":"Zhang H (1998) Mechanism of BRCA1 function. University of Pennsylvania, Philadelphia"},{"key":"10964_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0995-17","volume":"11","author":"ST Marquis","year":"1995","unstructured":"Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL, Chodosh LA (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17\u201326","journal-title":"Nat Genet"},{"key":"10964_CR41","unstructured":"Gottschalk AJ 2010 Biochemical and Developmental Characterization of a SNF2-like ATPase Amplified in Liver Cancer 1 (ALC1). In, University of Kansas"},{"key":"10964_CR42","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.1073\/pnas.1606220113","volume":"113","author":"B Alaei-Mahabadi","year":"2016","unstructured":"Alaei-Mahabadi B, Bhadury J, Karlsson JW, Nilsson JA, Larsson E (2016) Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers. Proc Natl Acad Sci 113:13768\u201313773","journal-title":"Proc Natl Acad Sci"},{"key":"10964_CR43","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1200\/JCO.2000.18.24.4045","volume":"18","author":"PO Chappuis","year":"2000","unstructured":"Chappuis PO, Kapusta L, B\u00e9gin LR, Wong N, Brunet J-S, Narod SA, Slingerland J, Foulkes WD (2000) Germline BRCA1\/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045\u20134052","journal-title":"J Clin Oncol"},{"key":"10964_CR44","unstructured":"Clark-Knowles KV 2007 Conditional inactivation of the BRCA1 tumour suppressor gene in the mouse ovarian surface epithelium in vitro and in vivo. In, University of Ottawa, Canada"},{"key":"10964_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700\u2013710","journal-title":"Am J Hum Genet"},{"key":"10964_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13402-011-0010-3","volume":"34","author":"P Van Der Groep","year":"2011","unstructured":"Van Der Groep P, Van Der Wall E, Van Diest PJ (2011) Pathology of hereditary breast cancer. Cell Oncol 34:71\u201388","journal-title":"Cell Oncol"},{"key":"10964_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fonc.2020.00361","volume":"10","author":"Y Hatano","year":"2020","unstructured":"Hatano Y, Tamada M, Matsuo M, Hara A (2020) Molecular trajectory of BRCA1 and BRCA2 mutations. Front Oncol 10:361","journal-title":"Front Oncol"},{"key":"10964_CR48","unstructured":"Pokharel H 2018 Developing a model of care to identify women at high risk of hereditary gynaecological cancer in developing nations. In, UNSW, Sydney"},{"key":"10964_CR49","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/genes12071034","volume":"12","author":"PR Andreassen","year":"2021","unstructured":"Andreassen PR, Seo J, Wiek C, Hanenberg H (2021) Understanding BRCA2 function as a tumor suppressor based on domain-specific activities in DNA damage responses. Genes 12:1034","journal-title":"Genes"},{"key":"10964_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2350-7-75","volume":"7","author":"S Saxena","year":"2006","unstructured":"Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC (2006) Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 7:1\u201312","journal-title":"BMC Med Genet"},{"key":"10964_CR51","doi-asserted-by":"publisher","DOI":"10.15761\/ICST.1000228","author":"I Godet","year":"2017","unstructured":"Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Therap. https:\/\/doi.org\/10.15761\/ICST.1000228","journal-title":"Integr Cancer Sci Therap"},{"key":"10964_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10897-006-9078-8","volume":"16","author":"W McKinnon","year":"2007","unstructured":"McKinnon W, Naud S, Ashikaga T, Colletti R, Wood M (2007) Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. J Genet Couns 16:433\u2013456","journal-title":"J Genet Couns"},{"key":"10964_CR53","first-page":"5","volume":"12","author":"CM Gosden","year":"1998","unstructured":"Gosden CM, Liloglou T, Nunn J, Gardener D, Nickson P, Crampton J, Field J (1998) The knights of the round table hypothesis of tumour suppressor gene function\u2013noble sacrifice or sexual dalliance: genes, including p53, BRCA1\/2 and RB have evolved by horizontal and vertical transmission of mating factor genes and are involved in gametogenesis, implantation, development and tumourigenesis. Int J Oncol 12:5\u201340","journal-title":"Int J Oncol"},{"key":"10964_CR54","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11010-022-04618-7","volume":"478","author":"MJ Akhtar","year":"2023","unstructured":"Akhtar MJ, Khan SA, Kumar B, Chawla P, Bhatia R, Singh K (2023) Role of sodium dependent SLC13 transporter inhibitors in various metabolic disorders. Mol Cell Biochem 478:1669\u20131687","journal-title":"Mol Cell Biochem"},{"key":"10964_CR55","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-021-23587-x","volume":"12","author":"C-Y Chang","year":"2021","unstructured":"Chang C-Y, Wang J, Zhao Y, Liu J, Yang X, Yue X, Wang H, Zhou F, Inclan-Rico JM, Ponessa JJ (2021) Tumor suppressor p53 regulates intestinal type 2 immunity. Nat Commun 12:3371","journal-title":"Nat Commun"},{"key":"10964_CR56","first-page":"174","volume":"88","author":"F Chang","year":"1993","unstructured":"Chang F, Syrj\u00e4nen S, Kurvinen K, Syrj\u00e4nen K (1993) The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol (Springer Nature) 88:174\u2013186","journal-title":"Am J Gastroenterol (Springer Nature)"},{"key":"10964_CR57","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jcb.30331","volume":"123","author":"MR Patil","year":"2022","unstructured":"Patil MR, Bihari A (2022) A comprehensive study of p53 protein. J Cell Biochem 123:1891\u20131937","journal-title":"J Cell Biochem"},{"key":"10964_CR58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","volume":"55","author":"D Freedman","year":"1999","unstructured":"Freedman D, Wu L, Levine A (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci CMLS 55:96\u2013107","journal-title":"Cell Mol Life Sci CMLS"},{"key":"10964_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1568009053332636","volume":"5","author":"E Rayburn","year":"2005","unstructured":"Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27\u201341","journal-title":"Curr Cancer Drug Targets"},{"key":"10964_CR60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.biopha.2018.06.066","volume":"106","author":"R Godone","year":"2018","unstructured":"Godone R, Leit\u00e3o G, Ara\u00fajo N, Castelletti C, Lima-Filho J, Martins D (2018) Clinical and molecular aspects of breast cancer: targets and therapies. Biomed Pharmacother 106:14\u201334","journal-title":"Biomed Pharmacother"},{"key":"10964_CR61","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol: Off J Am Soc Clin Oncol 25:1329","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10964_CR62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","volume":"96","author":"KA Metcalfe","year":"2005","unstructured":"Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B (2005) The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222\u2013226","journal-title":"Gynecol Oncol"},{"key":"10964_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","volume":"53","author":"K Kast","year":"2016","unstructured":"Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M (2016) Prevalence of BRCA1\/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet 53:465\u2013471","journal-title":"J Med Genet"},{"key":"10964_CR64","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/humu.20169","volume":"25","author":"S Mazoyer","year":"2005","unstructured":"Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25:415\u2013422","journal-title":"Hum Mutat"},{"key":"10964_CR65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-010-0817-z","volume":"125","author":"MD Sluiter","year":"2011","unstructured":"Sluiter MD, van Rensburg EJ (2011) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 125:325\u2013349","journal-title":"Breast Cancer Res Treat"},{"key":"10964_CR66","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrc3181-c3","volume":"12","author":"R Roy","year":"2012","unstructured":"Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: important differences with common interests. Nat Rev Cancer 12:372\u2013372","journal-title":"Nat Rev Cancer"},{"key":"10964_CR67","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2012","unstructured":"Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68\u201378","journal-title":"Nat Rev Cancer"},{"key":"10964_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0955-0674(03)00042-5","volume":"15","author":"LM Starita","year":"2003","unstructured":"Starita LM, Parvin JD (2003) The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 15:345\u2013350","journal-title":"Curr Opin Cell Biol"},{"key":"10964_CR69","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1006\/bbrc.2000.3983","volume":"279","author":"K Yamane","year":"2000","unstructured":"Yamane K, Katayama E, Tsuruo T (2000) The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. Biochem Biophys Res Commun 279:678\u2013684","journal-title":"Biochem Biophys Res Commun"},{"key":"10964_CR70","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/B978-0-323-96121-9.00006-1","volume-title":"Current molecular targets of heterocyclic compounds for cancer therapy","author":"NK Nandi","year":"2024","unstructured":"Nandi NK, Bhatia R, Chauhan G, Kalra S, Kumar B (2024) Cyclin-dependent kinase 4 and 6 in cancer: exploration of CDK4\/6 inhibitors as anticancer agents. Current molecular targets of heterocyclic compounds for cancer therapy. Elsevier, Amsterdam, pp 115\u2013137"},{"key":"10964_CR71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","volume":"10","author":"PL Welcsh","year":"2001","unstructured":"Welcsh PL, King M-C (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705\u2013713","journal-title":"Hum Mol Genet"},{"key":"10964_CR72","doi-asserted-by":"publisher","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M (2015) Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 7:a016600","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10964_CR73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0168-9525(99)01930-7","volume":"16","author":"PL Welcsh","year":"2000","unstructured":"Welcsh PL, Owens KN, King M-C (2000) Insights into the functions of BRCA1 and BRCA2. Trends Genet 16:69\u201374","journal-title":"Trends Genet"},{"key":"10964_CR74","doi-asserted-by":"publisher","first-page":"27722","DOI":"10.1039\/D3RA04029A","volume":"13","author":"MS Ayoup","year":"2023","unstructured":"Ayoup MS, Wahby Y, Abdel-Hamid H, Abu-Serie MM, Ramadan S, Barakat A, Teleb M, Ismail MM (2023) Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3\/7 and P53-MDM2 signaling for halting breast cancer. RSC Adv 13:27722\u201327737","journal-title":"RSC Adv"},{"key":"10964_CR75","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1039\/D3MD00251A","volume":"14","author":"G Girst","year":"2023","unstructured":"Girst G, Lopes EA, Gon\u00e7alves LM, Espadinha M, K\u00fasz N, Wang H-C, Santos MM, Hunyadi A (2023) Hybrid molecules of protoflavones and spirooxindole derivatives with selective cytotoxicity against triple-negative breast cancer cells. RSC Med Chem 14:1778\u20131786","journal-title":"RSC Med Chem"},{"key":"10964_CR76","doi-asserted-by":"publisher","first-page":"106124","DOI":"10.1016\/j.bioorg.2022.106124","volume":"129","author":"A Barakat","year":"2022","unstructured":"Barakat A, Alshahrani S, Al-Majid AM, Alamary AS, Haukka M, Abu-Serie MM, D\u00f6mling A, Mazyed EA, Badria FA, El-Senduny FF (2022) Novel spirooxindole based benzimidazole scaffold: in vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma. Bioorg Chem 129:106124","journal-title":"Bioorg Chem"},{"key":"10964_CR77","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2174\/1381612827666210625160627","volume":"28","author":"M Gouda","year":"2022","unstructured":"Gouda M, Bawzeer M, Hegazy L, Azab M, Elagawany M, Rateb M, Yaseen M, Elgendy B (2022) Design, synthesis and antitumor activity of novel Dispiro [oxindole-cyclohexanone]-pyrrolidines. Curr Pharm Des 28:198\u2013207","journal-title":"Curr Pharm Des"},{"key":"10964_CR78","doi-asserted-by":"publisher","first-page":"7178","DOI":"10.3390\/ijms23137178","volume":"23","author":"\u0141 Tomorowicz","year":"2022","unstructured":"Tomorowicz \u0141, \u017bo\u0142nowska B, Szafra\u0144ski K, Chojnacki J, Konopi\u0144ski R, Grzybowska EA, S\u0142awi\u0144ski J, Kawiak A (2022) New 2-[(4-Amino-6-N-substituted-1, 3, 5-triazin-2-yl) methylthio]-N-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide derivatives design, synthesis and anticancer evaluation. Int J Mol Sci 23:7178","journal-title":"Int J Mol Sci"},{"key":"10964_CR79","doi-asserted-by":"publisher","first-page":"114637","DOI":"10.1016\/j.ejmech.2022.114637","volume":"241","author":"M Espadinha","year":"2022","unstructured":"Espadinha M, Lopes EA, Marques V, Amaral JD, Dos Santos DJ, Mori M, Daniele S, Piccarducci R, Zappelli E, Martini C (2022) Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors. Eur J Med Chem 241:114637","journal-title":"Eur J Med Chem"},{"key":"10964_CR80","doi-asserted-by":"publisher","first-page":"104962","DOI":"10.1016\/j.jff.2022.104962","volume":"89","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wang Y, Sun Y, Zhao G, Wang J, Liu L, Liu F, Wang P, Xu X (2022) 4\u2032, 7-Di-O-methylnaringenin (DMNG), a naringenin derivative, activates p53 signal pathway through down-regulating MDM2. J Functional Foods 89:104962","journal-title":"J Functional Foods"},{"key":"10964_CR81","first-page":"864","volume":"21","author":"D Kumar","year":"2020","unstructured":"Kumar D, Sharma S, Kalra S, Singh G, Monga V, Kumar B (2020) Medicinal perspective of indole derivatives: recent developments and structure-activity relationship studies. Curr Drug Targets 21:864\u2013891","journal-title":"Curr Drug Targets"},{"key":"10964_CR82","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.bioorg.2021.105068","volume":"114","author":"D Kumar","year":"2021","unstructured":"Kumar D, Kumar RR, Pathania S, Singh PK, Kalra S, Kumar B (2021) Investigation of indole functionalized pyrazoles and oxadiazoles as anti-inflammatory agents: synthesis, in-vivo, in-vitro and in-silico analysis. Bioorg Chem 114:105068","journal-title":"Bioorg Chem"},{"key":"10964_CR83","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.3390\/molecules27123721","volume":"27","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ji B, Cheng Z, Zhang L, Cheng Y, Li Y, Ren J, Liu W, Ma Y (2022) Synthesis and biological evaluation of novel synthetic indolone derivatives as anti-tumor agents targeting p53-MDM2 and p53-MDMX. Molecules 27:3721","journal-title":"Molecules"},{"key":"10964_CR84","doi-asserted-by":"publisher","first-page":"735236","DOI":"10.3389\/fchem.2021.735236","volume":"9","author":"YMA Aziz","year":"2021","unstructured":"Aziz YMA, Lotfy G, Said MM, El Ashry ESH, El Tamany ESH, Soliman SM, Abu-Serie MM, Teleb M, Yousuf S, D\u00f6mling A (2021) Design, synthesis, chemical and biochemical insights into novel hybrid spirooxindole-based p53-MDM2 inhibitors with potential Bcl2 signaling attenuation. Front Chem 9:735236","journal-title":"Front Chem"},{"key":"10964_CR85","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.3390\/molecules26206305","volume":"26","author":"AM Al-Majid","year":"2021","unstructured":"Al-Majid AM, Ali M, Islam MS, Alshahrani S, Alamary AS, Yousuf S, Choudhary MI, Barakat A (2021) Stereoselective synthesis of the di-spirooxindole analogs based oxindole and cyclohexanone moieties as potential anticancer agents. Molecules 26:6305","journal-title":"Molecules"},{"key":"10964_CR86","doi-asserted-by":"publisher","first-page":"105427","DOI":"10.1016\/j.bioorg.2021.105427","volume":"117","author":"G Lotfy","year":"2021","unstructured":"Lotfy G, Aziz YMA, Said MM, El Sayed H, El Sayed H, Abu-Serie MM, Teleb M, D\u00f6mling A, Barakat A (2021) Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators. Bioorg Chem 117:105427","journal-title":"Bioorg Chem"},{"key":"10964_CR87","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10593-020-02726-0","volume":"56","author":"A Beloglazkina","year":"2020","unstructured":"Beloglazkina A, Barashkin A, Polyakov V, Kotovsky G, Karpov N, Mefedova S, Zagribelny B, Ivanenkov Y, Kalinina M, Skvortsov D (2020) Synthesis and biological evaluation of novel dispiro compounds based on 5-arylidenehydantoins and isatins as inhibitors of p53\u2013mdm2 protein\u2013protein interaction. Chem Heterocycl Compd 56:747\u2013755","journal-title":"Chem Heterocycl Compd"},{"key":"10964_CR88","doi-asserted-by":"publisher","first-page":"104369","DOI":"10.1016\/j.bioorg.2020.104369","volume":"105","author":"HA Gomaa","year":"2020","unstructured":"Gomaa HA, El-Sherief HA, Hussein S, Gouda AM, Salem OI, Alharbi KS, Hayallah AM, Youssif BG (2020) Novel 1, 2, 4-triazole derivatives as apoptotic inducers targeting p53: synthesis and antiproliferative activity. Bioorg Chem 105:104369","journal-title":"Bioorg Chem"},{"key":"10964_CR89","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1021\/acsomega.3c05098","volume":"9","author":"M Zia","year":"2024","unstructured":"Zia M, Parveen S, Shafiq N, Rashid M, Farooq A, Dauelbait M, Shahab M, Salamatullah AM, Brogi S, Bourhia M (2024) Exploring citrus sinensis phytochemicals as potential inhibitors for breast cancer genes BRCA1 and BRCA2 using pharmacophore modeling Molecular Docking, MD Simulations, and DFT Analysis. ACS Omega 9:2161\u20132182","journal-title":"ACS Omega"},{"key":"10964_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad156","author":"H-B Lee","year":"2023","unstructured":"Lee H-B, Lee K-H, Song SH, Kim K, Kim HK, Moon H-G, Han W, Lee D-W, Im S-A, Jang B-S (2023) A Survey of practice patterns for clinical nodal staging prior to neoadjuvant chemotherapy in breast cancer. The Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyad156","journal-title":"The Oncologist"},{"key":"10964_CR91","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O'Reilly","year":"2021","unstructured":"O\u2019Reilly D, Al Sendi M, Kelly CM (2021) Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 12:164","journal-title":"World J Clin Oncol"},{"key":"10964_CR92","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/1568009616666160928110818","volume":"17","author":"B Kumar","year":"2017","unstructured":"Kumar B, Kumar R, Skvortsova I, Kumar V (2017) Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials. Curr Cancer Drug Targets 17:357\u2013375","journal-title":"Curr Cancer Drug Targets"},{"key":"10964_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/adt.2022.085","volume":"21","author":"RRK Rawal","year":"2023","unstructured":"Rawal RRK, Gupta PK, Kumar B, Bhatia R (2023) Design, synthesis, and biological evaluation of novel Dihydropyrimidinone derivatives as potential anticancer agents and tubulin polymerization inhibitors. Assay Drug Dev Technol 21:17\u201328","journal-title":"Assay Drug Dev Technol"},{"key":"10964_CR94","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cncr.26351","volume":"118","author":"M Kriege","year":"2012","unstructured":"Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW (2012) The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 118:899\u2013907","journal-title":"Cancer"},{"key":"10964_CR95","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ctrv.2012.02.011","volume":"38","author":"S Murray","year":"2012","unstructured":"Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012) Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 38:890\u2013903","journal-title":"Cancer Treat Rev"},{"key":"10964_CR96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wi\u015bniowski R, Siolek M (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375\u2013379","journal-title":"J Clin Oncol"},{"key":"10964_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3332","author":"NC Turner","year":"2012","unstructured":"Turner NC, Tutt AN (2012) Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res. https:\/\/doi.org\/10.1186\/bcr3332","journal-title":"Breast Cancer Res"},{"key":"10964_CR98","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1158\/1078-0432.CCR-16-2174","volume":"23","author":"A Afghahi","year":"2017","unstructured":"Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang P-J, Schackmann E, Hartman A-R, Ford JM (2017) Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance. Clin Cancer Res 23:3365\u20133370","journal-title":"Clin Cancer Res"},{"key":"10964_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:1\u201316","journal-title":"BMC Med"},{"key":"10964_CR100","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord CJ, Tutt AN, Ashworth A (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 66:455\u2013470","journal-title":"Annu Rev Med"},{"key":"10964_CR101","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Tung N, Armstrong A, Dymond M (2023) OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 184:39\u201347","journal-title":"Eur J Cancer"},{"key":"10964_CR102","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-031-30065-3_6","volume-title":"Targeting the DNA damage response for cancer therapy","author":"F Lynce","year":"2023","unstructured":"Lynce F, Robson M (2023) Clinical Use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer. In: Yap TA, Shapiro GI (eds) Targeting the DNA damage response for cancer therapy. Springer, Berlin, pp 91\u2013102"},{"key":"10964_CR103","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16:255\u2013282","journal-title":"Target Oncol"},{"key":"10964_CR104","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.3390\/cancers14174332","volume":"14","author":"MCS Menezes","year":"2022","unstructured":"Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F (2022) PARP inhibitors for breast cancer: germline BRCA1\/2 and beyond. Cancers 14:4332","journal-title":"Cancers"},{"key":"10964_CR105","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2174\/1389557523666221208104530","volume":"23","author":"I Passi","year":"2023","unstructured":"Passi I, Salwan S, Kumar B (2023) US-FDA approved drugs in 2020 and 2021: a review. Mini Rev Med Chem 23:1273\u20131297","journal-title":"Mini Rev Med Chem"},{"key":"10964_CR106","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523\u2013533","journal-title":"N Engl J Med"},{"key":"10964_CR107","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753\u2013763","journal-title":"N Engl J Med"},{"key":"10964_CR108","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/bjc.2016.41","volume":"114","author":"Y Drew","year":"2016","unstructured":"Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D (2016) Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 114:723\u2013730","journal-title":"Br J Cancer"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10964-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T13:02:39Z","timestamp":1747314159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10964-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10964"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10964-z","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}